TAXUS IV Data Suggest Advantage For Paclitaxel-Eluting Stent In Diabetics
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is emphasizing the performance of its Taxus paclitaxel-eluting stent in diabetic patients as a possible edge over rival Johnson & Johnson's Cypher sirolimus-eluting stent
You may also be interested in...
Boston Scientific Floats Taxus Base Price; J&J Counters TAXUS IV In Court
Boston Scientific is invoking clinical data from the TAXUS IV trial's diabetic patient subset to thwart Johnson & Johnson's attempt to enjoin U.S. sales of the Express2 and Taxus stents
Boston Scientific Floats Taxus Base Price; J&J Counters TAXUS IV In Court
Boston Scientific is invoking clinical data from the TAXUS IV trial's diabetic patient subset to thwart Johnson & Johnson's attempt to enjoin U.S. sales of the Express2 and Taxus stents
Cordis Counters TAXUS IV With “New SIRIUS,” Critiques Angiographic Data
The revascularization rates associated with Boston Scientific's Taxus paclitaxel-eluting stent in TAXUS IV are "artificially" depressed by the relatively low rate of angiographic follow-up in the trial, according to rival Johnson & Johnson/Cordis